naftopidil and finasteride

naftopidil has been researched along with finasteride in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, H; Deng, ZA; Lv, DJ; Qian, YN; Shen, JL; Tian, XM; Wang, CL; Yu, YZ; Yuan, M; Zhang, HB; Zhang, JX; Zhao, SC	1
Andriole, GL; Bullock, TL	1
Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ	1

Reviews

1 review(s) available for naftopidil and finasteride

Article	Year
Emerging drug therapies for benign prostatic hyperplasia. Expert opinion on emerging drugs, 2006, Volume: 11, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Calcitriol; Cell Proliferation; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Indazoles; Male; Naphthalenes; Phytotherapy; Piperazines; Plant Extracts; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Serenoa	2006

Article

Year

Emerging drug therapies for benign prostatic hyperplasia.

Expert opinion on emerging drugs, 2006, Volume: 11, Issue:1

Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Calcitriol; Cell Proliferation; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Indazoles; Male; Naphthalenes; Phytotherapy; Piperazines; Plant Extracts; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Serenoa

2006

Trials

1 trial(s) available for naftopidil and finasteride

Article	Year
[Comparison of different drugs on the treatment of benign prostate hyperplasia]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2007, Jul-15, Volume: 45, Issue:14 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome	2007

Article

Year

[Comparison of different drugs on the treatment of benign prostate hyperplasia].

Zhonghua wai ke za zhi [Chinese journal of surgery], 2007, Jul-15, Volume: 45, Issue:14

Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome

2007

Other Studies

1 other study(ies) available for naftopidil and finasteride

Article	Year
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents. Bioorganic & medicinal chemistry, 2019, 01-01, Volume: 27, Issue:1 Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Molecular Structure; Piperazines; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship	2019

Article

Year

Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.

Bioorganic & medicinal chemistry, 2019, 01-01, Volume: 27, Issue:1

Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Molecular Structure; Piperazines; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship

2019